BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lees CW, Maan AK, Hansoti B, Satsangi J, Arnott ID. Tolerability and safety of mercaptopurine in azathioprine-intolerant patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2008;27:220-227. [PMID: 17988235 DOI: 10.1111/j.1365-2036.2007.03570.x] [Cited by in Crossref: 62] [Cited by in F6Publishing: 62] [Article Influence: 4.4] [Reference Citation Analysis]
Number Citing Articles
1 Moran GW, Lim AW, Bailey JL, Dubeau MF, Leung Y, Devlin SM, Novak K, Kaplan GG, Iacucci M, Seow C. Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2013;38:1002-1024. [PMID: 24099467 DOI: 10.1111/apt.12491] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 5.6] [Reference Citation Analysis]
2 Meggitt SJ, Anstey AV, Mohd Mustapa MF, Reynolds NJ, Wakelin S. British Association of Dermatologists’ guidelines for the safe and effective prescribing of azathioprine 2011. Br J Dermatol. 2011;165:711-734. [PMID: 21950502 DOI: 10.1111/j.1365-2133.2011.10575.x] [Cited by in Crossref: 76] [Cited by in F6Publishing: 53] [Article Influence: 8.4] [Reference Citation Analysis]
3 Blaker PA, Arenas-hernandez M, Marinaki AM, Sanderson JD. The pharmacogenetic basis of individual variation in thiopurine metabolism. Personalized Medicine 2012;9:707-25. [DOI: 10.2217/pme.12.85] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
4 Kiefer K, El-matary W. 6-mercaptopurine as an alternative to azathioprine in azathioprine-induced hepatoxicity: . Inflammatory Bowel Diseases 2009;15:318-9. [DOI: 10.1002/ibd.20603] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
5 Nagamine A, Takenaka M, Aomori T, Okada Y, Hiromura K, Nojima Y, Araki T, Nakamura T, Yamamoto K. Effect of genetic polymorphisms on effectiveness of low-dose azathioprine in Japanese patients with systemic lupus erythematosus. American Journal of Health-System Pharmacy 2012;69:2072-8. [DOI: 10.2146/ajhp120179] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
6 Daperno M, Sostegni R, Canaparo R, Serpe L, Lavagna A, Crocellà L, Castagno F, Vernetto A, Rigazio C, Ercole E. Prospective study of the effects of concomitant medications on thiopurine metabolism in inflammatory bowel disease. Aliment Pharmacol Ther. 2009;30:843-853. [PMID: 19650826 DOI: 10.1111/j.1365-2036.2009.04106.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
7 Ban H, Andoh A, Imaeda H, Kobori A, Bamba S, Tsujikawa T, Sasaki M, Saito Y, Fujiyama Y. The multidrug-resistance protein 4 polymorphism is a new factor accounting for thiopurine sensitivity in Japanese patients with inflammatory bowel disease. J Gastroenterol. 2010;45:1014-1021. [PMID: 20393862 DOI: 10.1007/s00535-010-0248-y] [Cited by in Crossref: 73] [Cited by in F6Publishing: 68] [Article Influence: 7.3] [Reference Citation Analysis]
8 Stocco G, Cuzzoni E, Iudicibus SD, Favretto D, Malusà N, Martelossi S, Pozzi E, Lionetti P, Ventura A, Decorti G. Thiopurine metabolites variations during co-treatment with aminosalicylates for inflammatory bowel disease: Effect of N-acetyl transferase polymorphisms. World J Gastroenterol 2015; 21(12): 3571-3578 [PMID: 25834322 DOI: 10.3748/wjg.v21.i12.3571] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
9 Andrejic J, Rojas-balcazar J, Dennis M, Berkelhammer C. Azathioprine-induced hypersensitivity hepatitis: Tolerance to 6-mercaptopurine: . Inflammatory Bowel Diseases 2010;16:1828-9. [DOI: 10.1002/ibd.21240] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
10 Amin J, Huang B, Yoon J, Shih DQ. Update 2014: advances to optimize 6-mercaptopurine and azathioprine to reduce toxicity and improve efficacy in the management of IBD. Inflamm Bowel Dis. 2015;21:445-452. [PMID: 25248004 DOI: 10.1097/mib.0000000000000197] [Cited by in Crossref: 47] [Cited by in F6Publishing: 28] [Article Influence: 7.8] [Reference Citation Analysis]
11 Kennedy NA, Rhatigan E, Arnott ID, Noble CL, Shand AG, Satsangi J, Lees CW. A trial of mercaptopurine is a safe strategy in patients with inflammatory bowel disease intolerant to azathioprine: an observational study, systematic review and meta-analysis. Aliment Pharmacol Ther. 2013;38:1255-1266. [PMID: 24117596 DOI: 10.1111/apt.12511] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 5.9] [Reference Citation Analysis]
12 Chaparro M, Ordás I, Cabré E, Garcia-sanchez V, Bastida G, Peñalva M, Gomollón F, García-planella E, Merino O, Gutiérrez A, Esteve M, Márquez L, Garcia-sepulcre M, Hinojosa J, Vera I, Muñoz F, Mendoza JL, Cabriada JL, Montoro MA, Barreiro-de Acosta M, Ceña G, Saro C, Aldeguer X, Barrio J, Maté J, Gisbert JP. Safety of Thiopurine Therapy in Inflammatory Bowel Disease: Long-term Follow-up Study of 3931 Patients. Inflammatory Bowel Diseases 2013;19:1404-10. [DOI: 10.1097/mib.0b013e318281f28f] [Cited by in Crossref: 178] [Cited by in F6Publishing: 62] [Article Influence: 22.3] [Reference Citation Analysis]
13 Levesque BG, Loftus EV. Initiating azathioprine for Crohn’s disease. Clin Gastroenterol Hepatol. 2012;10:460-465. [PMID: 22330233 DOI: 10.1016/j.cgh.2012.01.018] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
14 Hanauer SB, Sandborn WJ, Lichtenstein GR. Evolving Considerations for Thiopurine Therapy for Inflammatory Bowel Diseases-A Clinical Practice Update: Commentary. Gastroenterology 2019;156:36-42. [PMID: 30195449 DOI: 10.1053/j.gastro.2018.08.043] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
15 Kornbluth A, Sachar DB;  Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105:501-23; quiz 524. [PMID: 20068560 DOI: 10.1038/ajg.2009.727] [Cited by in Crossref: 826] [Cited by in F6Publishing: 730] [Article Influence: 75.1] [Reference Citation Analysis]
16 Ledder OD, Lemberg DA, Ooi CY, Day AS. Are thiopurines always contraindicated after thiopurine-induced pancreatitis in inflammatory bowel disease? J Pediatr Gastroenterol Nutr. 2013;57:583-586. [PMID: 23783022 DOI: 10.1097/mpg.0b013e31829f16fc] [Cited by in Crossref: 23] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
17 Beswick L, Friedman AB, Sparrow MP. The role of thiopurine metabolite monitoring in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2014;8:383-92. [PMID: 24684593 DOI: 10.1586/17474124.2014.894878] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
18 Lammert C, Loy VM, Oshima K, Gawrieh S. Management of Difficult Cases of Autoimmune Hepatitis. Curr Gastroenterol Rep. 2016;18:9. [PMID: 26780632 DOI: 10.1007/s11894-015-0484-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
19 van Gerven NM, de Boer YS, Mulder CJ, van Nieuwkerk CM, Bouma G. Auto immune hepatitis. World J Gastroenterol 2016; 22(19): 4651-4661 [PMID: 27217697 DOI: 10.3748/wjg.v22.i19.4651] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
20 Aldhous MC, Satsangi J. The impact of smoking in Crohn's disease: no smoke without fire. Frontline Gastroenterol 2010;1:156-64. [PMID: 28839569 DOI: 10.1136/fg.2010.001487] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
21 Vasudevan A, Beswick L, Friedman AB, Moltzen A, Haridy J, Raghunath A, Sparrow M, van Langenberg D. Low-dose thiopurine with allopurinol co-therapy overcomes thiopurine intolerance and allows thiopurine continuation in inflammatory bowel disease. Digestive and Liver Disease 2018;50:682-8. [DOI: 10.1016/j.dld.2018.02.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
22 Raj LS, Hawthorne AB. Optimising use of thiopurines in inflammatory bowel disease. Frontline Gastroenterol 2010;1:44-51. [PMID: 28839543 DOI: 10.1136/fg.2009.000174] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
23 Ledder O, Lemberg DA, Day AS. Thiopurine-induced pancreatitis in inflammatory bowel diseases. Expert Rev Gastroenterol Hepatol 2015;9:399-403. [PMID: 25494551 DOI: 10.1586/17474124.2015.992879] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
24 高树娟, 施瑞华. 炎症性肠病治疗的新进展. 世界华人消化杂志 2012; 20(36): 3742-3747 [DOI: 10.11569/wcjd.v20.i36.3742] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Jagt JZ, Pothof CD, Buiter HJC, van Limbergen JE, van Wijk MP, Benninga MA, de Boer NKH, de Meij TGJ. Adverse Events of Thiopurine Therapy in Pediatric Inflammatory Bowel Disease and Correlations with Metabolites: A Cohort Study. Dig Dis Sci 2021. [PMID: 33532972 DOI: 10.1007/s10620-021-06836-3] [Reference Citation Analysis]
26 Ansari A, Patel N, Sanderson J, O’Donohue J, Duley JA, Florin TH. Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2010;31:640-647. [PMID: 20015102 DOI: 10.1111/j.1365-2036.2009.04221.x] [Cited by in Crossref: 105] [Cited by in F6Publishing: 91] [Article Influence: 8.8] [Reference Citation Analysis]
27 Sato T, Takagawa T, Kakuta Y, Nishio A, Kawai M, Kamikozuru K, Yokoyama Y, Kita Y, Miyazaki T, Iimuro M, Hida N, Hori K, Ikeuchi H, Nakamura S. NUDT15, FTO, and RUNX1 genetic variants and thiopurine intolerance among Japanese patients with inflammatory bowel diseases. Intest Res 2017;15:328-37. [PMID: 28670229 DOI: 10.5217/ir.2017.15.3.328] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
28 Choi CH, Kim Y, Kim YS, Ye BD, Lee KM, Lee BI, Jung S, Kim WH, Lee H; IBD Study Group of the Korean Association for the Study of Intestinal Diseases. Guidelines for the Management of Ulcerative Colitis. Intest Res 2012;10:1. [DOI: 10.5217/ir.2012.10.1.1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 1.1] [Reference Citation Analysis]
29 Goldberg R, Irving PM. Toxicity and response to thiopurines in patients with inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2015;9:891-900. [PMID: 25915575 DOI: 10.1586/17474124.2015.1039987] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
30 Gisbert JP, Chaparro M, Gomollón F. Common misconceptions about 5-aminosalicylates and thiopurines in inflammatory bowel disease. World J Gastroenterol 2011; 17(30): 3467-3478 [PMID: 21941413 DOI: 10.3748/wjg.v17.i30.3467] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]
31 Cohn HM, Dave M, Loftus EV. Understanding the Cautions and Contraindications of Immunomodulator and Biologic Therapies for Use in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017;23:1301-1315. [PMID: 28708806 DOI: 10.1097/mib.0000000000001199] [Cited by in Crossref: 17] [Cited by in F6Publishing: 5] [Article Influence: 5.7] [Reference Citation Analysis]
32 Smith MR, Cooper SC. Mycophenolate mofetil therapy in the management of inflammatory bowel disease--a retrospective case series and review. J Crohns Colitis. 2014;8:890-897. [PMID: 24507162 DOI: 10.1016/j.crohns.2014.01.014] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
33 De Boer NK, Van Bodegraven AA. Get the Best Out of Thiopurine Therapy. Gastroenterology 2014;146:865. [DOI: 10.1053/j.gastro.2013.08.062] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
34 Moffatt D, Bernstein CN. State-of-the-Art Medical Therapy of the Adult Patient with IBD: The Immunomodulators. In: Cohen RD, editor. Inflammatory Bowel Disease. Totowa: Humana Press; 2011. pp. 93-110. [DOI: 10.1007/978-1-60327-433-3_7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
35 Pitchumoni CS, Rubin A, Das K. Pancreatitis in Inflammatory Bowel Diseases. Journal of Clinical Gastroenterology 2010;44:246-53. [DOI: 10.1097/mcg.0b013e3181cadbe1] [Cited by in Crossref: 60] [Cited by in F6Publishing: 24] [Article Influence: 5.5] [Reference Citation Analysis]
36 Meijer B, Seinen ML, Leijte NN, Mulder CJ, van Bodegraven AA, de Boer NK. Clinical Value of Mercaptopurine After Failing Azathioprine Therapy in Patients With Inflammatory Bowel Disease. Ther Drug Monit. 2016;38:463-470. [PMID: 27158876 DOI: 10.1097/ftd.0000000000000312] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
37 Lakatos PL, Kiss LS. Current status of thiopurine analogues in the treatment in Crohn's disease. World J Gastroenterol 2011; 17(39): 4372-4381 [PMID: 22110262 DOI: 10.3748/wjg.v17.i39.4372] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
38 Nagy F, Molnár T, Szepes Z, Farkas K, Nyári T, Lonovics J. Efficacy of 6-mercaptopurine treatment after azathioprine hypersensitivity in inflammatory bowel disease. World J Gastroenterol 2008; 14(27): 4342-4346 [PMID: 18666323 DOI: 10.3748/wjg.14.4342] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
39 McLean LP, Cross RK. Adverse events in IBD: to stop or continue immune suppressant and biologic treatment. Expert Rev Gastroenterol Hepatol 2014;8:223-40. [PMID: 24490595 DOI: 10.1586/17474124.2014.881715] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 6.7] [Reference Citation Analysis]
40 Bermejo F, Aguas M, Chaparro M, Domènech E, Echarri A, García-Planella E, Guerra I, Gisbert JP, López-Sanromán A; en representación de GETECCU. Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the use of thiopurines in inflammatory bowel disease. Gastroenterol Hepatol 2018;41:205-21. [PMID: 29357999 DOI: 10.1016/j.gastrohep.2017.11.007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 5.3] [Reference Citation Analysis]
41 Calafat M, Mañosa M, Mesonero F, Guardiola J, Mínguez M, Nos P, Vera I, Taxonera C, Iglesias E, Ricart E, Gisbert JP, Calvet X, García-López S, Monfort D, Pérez Calle JL, Riestra S, Gomollón F, Garcia-Planella E, Bermejo F, Hernández V, Martín-Arranz MD, Gutiérrez A, Torres P, Cañete F, Domènech E; ENEIDA registry of GETECCU . Switching to a Second Thiopurine in Adult and Elderly Patients With Inflammatory Bowel Disease: A Nationwide Study From the ENEIDA Registry. J Crohns Colitis 2020;14:1290-8. [PMID: 32201893 DOI: 10.1093/ecco-jcc/jjaa055] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
42 Minakshi P, Kumar R, Ghosh M, Brar B, Barnela M, Lakhani P. Application of Polymeric Nano-Materials in Management of Inflammatory Bowel Disease. Curr Top Med Chem 2020;20:982-1008. [PMID: 32196449 DOI: 10.2174/1568026620666200320113322] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
43 Rogler G. Gastrointestinal and liver adverse effects of drugs used for treating IBD. Best Pract Res Clin Gastroenterol. 2010;24:157-165. [PMID: 20227029 DOI: 10.1016/j.bpg.2009.10.011] [Cited by in Crossref: 88] [Cited by in F6Publishing: 77] [Article Influence: 8.0] [Reference Citation Analysis]
44 Ha C, Dassopoulos T. Thiopurine therapy in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2010;4:575-588. [PMID: 20932143 DOI: 10.1586/egh.10.59] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
45 Frei P, Biedermann L, Nielsen OH, Rogler G. Use of thiopurines in inflammatory bowel disease. World J Gastroenterol 2013; 19(7): 1040-1048 [PMID: 23467510 DOI: 10.3748/wjg.v19.i7.1040] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
46 Leong RW, Gearry RB, Sparrow MP. Thiopurine hepatotoxicity in inflammatory bowel disease: the role for adding allopurinol. Expert Opin Drug Saf. 2008;7:607-616. [PMID: 18759713 DOI: 10.1517/14740338.7.5.607] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 2.0] [Reference Citation Analysis]
47 Asada A, Nishida A, Shioya M, Imaeda H, Inatomi O, Bamba S, Kito K, Sugimoto M, Andoh A. NUDT15 R139C-related thiopurine leukocytopenia is mediated by 6-thioguanine nucleotide-independent mechanism in Japanese patients with inflammatory bowel disease. J Gastroenterol. 2016;51:22-29. [PMID: 26590936 DOI: 10.1007/s00535-015-1142-4] [Cited by in Crossref: 58] [Cited by in F6Publishing: 59] [Article Influence: 9.7] [Reference Citation Analysis]
48 Osaki R, Imaeda H, Ban H, Aomatsu T, Bamba S, Tsujikawa T, Sasaki M, Fujiyama Y, Andoh A. Accuracy of genotyping using the TaqMan PCR assay for single nucleotide polymorphisms responsible for thiopurine sensitivity in Japanese patients with inflammatory bowel disease. Exp Ther Med 2011;2:783-6. [PMID: 22977575 DOI: 10.3892/etm.2011.287] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
49 Modén O, Mannervik B. Glutathione transferases in the bioactivation of azathioprine. Adv Cancer Res 2014;122:199-244. [PMID: 24974183 DOI: 10.1016/B978-0-12-420117-0.00006-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 2.2] [Reference Citation Analysis]
50 Bradford K, Shih DQ. Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease. World J Gastroenterol 2011; 17(37): 4166-4173 [PMID: 22072847 DOI: 10.3748/wjg.v17.i37.4166] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 43] [Article Influence: 4.1] [Reference Citation Analysis]
51 Dewit O, Starkel P, Roblin X. Thiopurine metabolism monitoring: implications in inflammatory bowel diseases. Eur J Clin Invest. 2010;40:1037-1047. [PMID: 20629710 DOI: 10.1111/j.1365-2362.2010.02346.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
52 Lim SZ, Chua EW. Revisiting the Role of Thiopurines in Inflammatory Bowel Disease Through Pharmacogenomics and Use of Novel Methods for Therapeutic Drug Monitoring. Front Pharmacol. 2018;9:1107. [PMID: 30349479 DOI: 10.3389/fphar.2018.01107] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 8.0] [Reference Citation Analysis]
53 Srinath AI, Gupta N, Husain SZ. Probing the association of pancreatitis in inflammatory bowel disease. Inflamm Bowel Dis. 2016;22:465-475. [PMID: 26535870 DOI: 10.1097/mib.0000000000000611] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
54 Cheifetz AS. Management of active Crohn disease. JAMA 2013;309:2150-8. [PMID: 23695484 DOI: 10.1001/jama.2013.4466] [Cited by in Crossref: 72] [Cited by in F6Publishing: 55] [Article Influence: 9.0] [Reference Citation Analysis]
55 Kuriyama M, Kato J, Suzuki H, Akita M, Hiraoka S, Okada H, Yamamoto K. TOLERABILITY AND USEFULNESS OF MERCAPTOPURINE IN AZATHIOPRINE-INTOLERANT JAPANESE PATIENTS WITH ULCERATIVE COLITIS: TOLERABILITY OF 6-MP IN UC PATIENTS. Digestive Endoscopy 2010;22:289-96. [DOI: 10.1111/j.1443-1661.2010.01009.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
56 Chang JY, Cheon JH. Thiopurine Therapy in Patients With Inflammatory Bowel Disease: A Focus on Metabolism and Pharmacogenetics. Dig Dis Sci 2019;64:2395-403. [PMID: 31290039 DOI: 10.1007/s10620-019-05720-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
57 Bamba S, Tsujikawa T, Sasaki M, Fujiyama Y, Andoh A. Immunomodulators and immunosuppressants for Japanese patients with ulcerative colitis. ISRN Gastroenterol. 2011;2011:194324. [PMID: 21991497 DOI: 10.5402/2011/194324] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
58 Bossa F, Annese V, Valvano MR, Latiano A, Martino G, Rossi L, Magnani M, Palmieri O, Serafini S, Damonte G, De Santo E, Andriulli A. Erythrocytes-mediated delivery of dexamethasone 21-phosphate in steroid-dependent ulcerative colitis: a randomized, double-blind Sham-controlled study. Inflamm Bowel Dis 2013;19:1872-9. [PMID: 23714676 DOI: 10.1097/MIB.0b013e3182874065] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
59 Choi CH, Kim YH, Kim YS, Ye BD, Lee KM, Lee BI, Jung SA, Kim WH, Lee H; IBD Study Group of the Korean Association for the Study of Intestinal Diseases. [Guidelines for the management of ulcerative colitis]. Korean J Gastroenterol. 2012;59:118-140. [PMID: 22387836 DOI: 10.4166/kjg.2012.59.2.118] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
60 Hoentjen F, Seinen ML, Hanauer SB, de Boer NK, Rubin DT, Bouma G, Harrell LE, van Bodegraven AA. Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:363-369. [PMID: 22605661 DOI: 10.1002/ibd.23021] [Cited by in Crossref: 72] [Cited by in F6Publishing: 63] [Article Influence: 9.0] [Reference Citation Analysis]
61 Levesque BG, Loftus EV. Medical Management of Ulcerative Colitis: Conventional Therapy—Azathioprine. In: Baumgart DC, editor. Crohn's Disease and Ulcerative Colitis. Cham: Springer International Publishing; 2017. pp. 413-9. [DOI: 10.1007/978-3-319-33703-6_40] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
62 Hübener S, Oo YH, Than NN, Hübener P, Weiler-normann C, Lohse AW, Schramm C. Efficacy of 6-Mercaptopurine as Second-Line Treatment for Patients With Autoimmune Hepatitis and Azathioprine Intolerance. Clinical Gastroenterology and Hepatology 2016;14:445-53. [DOI: 10.1016/j.cgh.2015.09.037] [Cited by in Crossref: 54] [Cited by in F6Publishing: 43] [Article Influence: 10.8] [Reference Citation Analysis]